Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Supernus Pharmaceuticals, Inc.
EIR
•Supernus Pharmaceuticals, Inc.•February 3, 2017

Supernus Pharmaceuticals, Inc. – FDA EIR, Feb 3, 2017

Record Details

An FDA surveillance inspection of Supernus Pharmaceuticals, Inc. in Rockville, MD, was conducted from January 31 to February 3, 2017. The inspection focused on the company's Postmarketing Adverse Drug Experience (PADE) reporting program, governed by regulations such as 21 CFR 314.80(c)(2). The primary violation documented in an FDA Form 483 observation concerned the late submission of Periodic Safety Update Reports (PSURs). Supernus Pharmaceuticals failed to submit four PSURs for Trokendi XR and six PSURs for Oxtellar XR within the required 30-day timeframe after the close of the reporting quarter. These late submissions constituted approximately 40% of all PSURs filed for these products since their respective approvals. Additionally, management received verbal recommendations for improvement. These included an instance of a late 15-day adverse event report submission in 2014 (though corrected since transitioning to electronic submissions), a significant gap of 15 months where pharmacovigilance responsibilities with a licensing partner (Stendhal) were not formally documented, and the absence of a formal process to verify information extracted from source documents by their outsourced pharmacovigilance provider. The company's Vice President of Quality acknowledged the formal observation and committed to providing a written response within 15 business days.

Company
Supernus Pharmaceuticals, Inc.
Inspection date
February 3, 2017
Product type
drugs
Office
Center for Drug Evaluation and Research
People
  • Jonathan W. Chapman (investigator)
  • Chaltu N.Wakijra (Senior Program Coordinator)
  • Frank G. Mottola (recipient)
  • Lori Ann Sullivan (company_representative)
  • Jim Gorski (company_representative)
View Company Profile

ID · 8eedef50-ccfb-42f7-862f-6f8a5215ee59

Violation Codes5
21 CFR 31021 CFR 31421 CFR 60021 CFR 60121 CFR 314.80(c)(2)

Full citation text and observation details available on the Dashboard.

Other documents for Supernus Pharmaceuticals, Inc.
  • 483 - 2017-02-03February 3, 2017
  • CRL

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Supernus Pharmaceuticals, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.